All In Biotech

Drug Trial Radar · NCT03114943

Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age

A Multi-national, Multi-center, Randomized, Double Blinded, Parallel-group Study to Assess the Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age

Last checked: Nov 19, 2026Latest source record: May 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 516 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

516

Actual

Start

Jul 14, 2016

Primary completion

Jun 28, 2017

Study completion Jun 28, 2017

Sponsor

Lead sponsor
SK Bioscience Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 14, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 12 months, up to 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study assesses non-inferiority by comparing seroconversion rate of NBP608 to Varivax which are indicated for active immunization for prevention of varicella. Total of 488 subjects (244 subjects per treatment arm) of 12 months to 12 years of age are enrolled, and each subject is administered with single dose of vaccine which is randomly assigned.

Conditions

  • Varicella

Interventions

  • NBP608Biological

    Preparation of the Oka/SK strain of live, attenuated varicella virus

  • VarivaxBiological

    Preparation of the Oka/Merck strain of live, attenuated varicella virus

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. seroconversion rate by FAMA (Fluorescent Antibody to Membrane Antigen) assayTime frame: 6 weeks after IP(Investigational Product) vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • De La Salle Health Sciences Institute

    Dasmariñas, Cavite, Philippines

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.